2gmx: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2gmx.gif|left|200px]] | [[Image:2gmx.gif|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_2gmx", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
| | --> | ||
| | {{STRUCTURE_2gmx| PDB=2gmx | SCENE= }} | ||
}} | |||
'''Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity''' | '''Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity''' | ||
| Line 27: | Line 24: | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
[[Category: Abad-Zapatero, C.]] | [[Category: Abad-Zapatero, C.]] | ||
[[Category: | [[Category: Aminopyridine-based c-jun n-terminal kinase inhibitor]] | ||
[[Category: | [[Category: C-jun n-terminal kinase]] | ||
[[Category: | [[Category: Jnk1]] | ||
[[Category: | [[Category: Protein kinase jnk1 inhibitor]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 05:17:23 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
Revision as of 05:17, 4 May 2008
Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity
OverviewOverview
The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1,000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38alpha, and p38delta and showed little inhibitory activity against a panel of 74 kinases.
About this StructureAbout this Structure
2GMX is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity., Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ, Haasch DL, Wang S, Clampit JE, Johnson EF, Lubben TH, Stashko MA, Olejniczak ET, Sun C, Dorwin SA, Haskins K, Abad-Zapatero C, Fry EH, Hutchins CW, Sham HL, Rondinone CM, Trevillyan JM, J Med Chem. 2006 Jun 15;49(12):3563-80. PMID:16759099 Page seeded by OCA on Sun May 4 05:17:23 2008